Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Eton Pharmaceuticals (Nasdaq: ETON), a company focused on developing and commercializing treatments for rare diseases, has announced it will report its second quarter 2024 financial results on Thursday, August 8, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON), a company focused on developing and commercializing treatments for rare diseases, has announced it will report its second quarter 2024 financial results on Thursday, August 8, 2024. The company will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results.
Management will take live questions from call participants and answer emailed questions from investors. Investors can email their questions to investorrelations@etonpharma.com. The live webcast will be accessible on Eton's website, with an archived version available for 30 days after the event.
Details
News Market Reaction – ETON
The recorded move for ETON in the trading session of this news was +1.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Dial in* (Audio Only) | Click Here |
| Webcast: | Click Here |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.